- Home
- BRKL vs RCUS Comparison
BRKL vs RCUS Comparison
Compare BRKL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- RCUS
- Stock Information
- Founded
- BRKL 1871
- RCUS 2015
- Country
- BRKL United States
- RCUS United States
- Employees
- BRKL N/A
- RCUS N/A
- Industry
- BRKL Savings Institutions
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BRKL Finance
- RCUS Health Care
- Exchange
- BRKL Nasdaq
- RCUS Nasdaq
- Market Cap
- BRKL 990.8M
- RCUS 1.2B
- IPO Year
- BRKL 1998
- RCUS 2018
- Fundamental
- Price
- BRKL $10.88
- RCUS $7.71
- Analyst Decision
- BRKL Buy
- RCUS Strong Buy
- Analyst Count
- BRKL 3
- RCUS 10
- Target Price
- BRKL $14.17
- RCUS $29.50
- AVG Volume (30 Days)
- BRKL 489.4K
- RCUS 905.1K
- Earning Date
- BRKL 04-23-2025
- RCUS 05-07-2025
- Dividend Yield
- BRKL 4.95%
- RCUS N/A
- EPS Growth
- BRKL N/A
- RCUS N/A
- EPS
- BRKL 0.77
- RCUS N/A
- Revenue
- BRKL $333,556,000.00
- RCUS $258,000,000.00
- Revenue This Year
- BRKL $55.25
- RCUS N/A
- Revenue Next Year
- BRKL $40.04
- RCUS $25.77
- P/E Ratio
- BRKL $14.16
- RCUS N/A
- Revenue Growth
- BRKL 0.04
- RCUS 120.51
- 52 Week Low
- BRKL $8.01
- RCUS $7.51
- 52 Week High
- BRKL $13.15
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- BRKL 38.91
- RCUS 26.87
- Support Level
- BRKL $10.74
- RCUS $8.02
- Resistance Level
- BRKL $11.15
- RCUS $8.57
- Average True Range (ATR)
- BRKL 0.22
- RCUS 0.43
- MACD
- BRKL 0.03
- RCUS -0.02
- Stochastic Oscillator
- BRKL 30.65
- RCUS 8.35
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.